Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.58 |
| ▸ | CYP19A1 known ✓ | P11511 | 2/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.42 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.42 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.93 |
| ▸ | MEN1 | O00255 | 4/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL504482 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2565398 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29378721 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29497777 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL94882 | 1.00 | TDP1 (0.93) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL30078382 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28836366 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1646515 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9355084 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL866164 | 0.97 | TDP1 (0.88) | TDP1KMT2AMEN1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220354902-A1 | METHODS OF GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVO | MESOBLAST, INC. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3424514-B1 | TNAP+ MESENCHYMAL PRECURSOR CELLS FOR USE IN TREATING CONNECTIVE TISSUE DISEASES | MESOBLAST INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-10609922-B2 | Protection of progenitor cells and regulation of their differentiation | PROTEOBIOACTIVES PTY LTD (AU) | 2020-04-07 | — | — | US | disclosed |
| US-20200101118-A1 | METHODS OF GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVO | MESOBLAST, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| US-10322166-B2 | Composition and method for the treatment or prevention of spinal disorders | KUNOVUS PTY LTD (AU) | 2019-06-18 | — | — | US | disclosed |
| EP-3424514-A1 | METHOD FOR GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVO | Mesoblast, Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2185165-B1 | STRO-1bright CELLS FOR USE IN TREATING CONNECTIVE TISSUE DISEASES | MESOBLAST INC (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20180206480-A1 | PROTECTION OF PROGENITOR CELLS AND REGULATION OF THEIR DIFFERENTIATION | PROTEOBIOACTIVES PTY LTD (AU) | 2018-07-26 | — | — | US | disclosed |
| US-9888679-B2 | Protection of progenitor cells and regulation of their differentiation | PROTEOBIOACTIVES PTY LTD (AU) | 2018-02-13 | — | — | US | disclosed |
| EP-2229436-B1 | PROTECTION OF PROGENITOR CELLS AND REGULATION OF THEIR DIFFERENTIATION | PROTEOBIOACTIVES PTY LTD (AU) | 2017-08-30 | — | — | EP | disclosed |
| EP-0960117-B1 | FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS (FHFs) AND METHODS OF USE | UNIV JOHNS HOPKINS MED (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1763362-A1 | USE OF MORPHOGENIC PROTEINS FOR TREATING CARTILAGE DEFECTS | STRYKER CORPORATION (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060194726-A1 | Methods of treating cartilage defects | STRYKER CORPORATION | 2006-08-31 | — | — | US | disclosed |
| WO-2005115438-A1 | USE OF MORPHOGENIC PROTEINS FOR TREATING CARTILAGE DEFECTS | STRYKER CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20040102379-A1 | Fibroblast growth factor homologous factors (FHFs) and methods of use | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2004-05-27 | — | — | US | disclosed |
| US-6635744-B1 | Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2003-10-21 | — | — | US | disclosed |
| EP-0960117-A4 | FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS (FHFs) AND METHODS OF USE | UNIV JOHNS HOPKINS MED (US) | 2000-06-14 | — | — | EP | disclosed |
| US-6020189-A | Fibroblast growth factor homologous factors (FHFs) and methods of use | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0960117-A1 | FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS (FHFs) AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998008864-A1 | FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS (FHFs) AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10609922-B2 | Protection of progenitor cells and regulation of their differentiation | CD44, MCL1, NES | KCNH2 4383/4885CYP19A1 4732/4885GAA 1551/4885 |
| US-20180206480-A1 | PROTECTION OF PROGENITOR CELLS AND REGULATION OF THEIR DIFFERENTIATION | CD44, MCL1, NES | KCNH2 4383/4885CYP19A1 4732/4885GAA 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.